NCT01510132

Travacom Post Marketing Surveillance Study

Post Marketing Surveillance Study to Evaluate the Safety Profile of Travacom (Travoprost/Timolol Fixed Combination) in Patients With Open-Angle Glaucoma or Ocular Hypertension Across India

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Alcon Research · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this multi-center, open label, single arm, post-marketing surveillance study is to assess the safety of Travacom in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers, prostaglandins, or other intraocular pressure-lowering (IOP) medication and when use of Travacom is considered appropriate.

Conditions

• Open-angle Glaucoma
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	Travoprost/timolol fixed combination (Travacom)	Commercially-marketed drug for the treatment of open-angle glaucoma or ocular hypertension

Timeline

• Start date: 2012-01-01
• Primary completion: 2012-01-01
• Completion: 2012-01-01
• First posted: 2012-01-13
• Last updated: 2012-10-18